Elite Pharma Inc
(ELTP)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 03/31
(Values in U.S. thousands)
| 03-2025 | 03-2024 | 03-2023 | 03-2022 | 03-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -4,315 | 20,109 | 3,562 | 8,898 | 5,088 |
| Depreciation Amortization | 2,137 | 1,518 | 1,345 | 1,435 | 1,525 |
| Income taxes - deferred | 3,795 | -19,989 | N/A | -2,172 | N/A |
| Accounts receivable | -9,905 | -16,595 | -37 | 439 | 611 |
| Other Working Capital | -15,166 | -11,894 | -2,012 | -1,010 | -2,058 |
| Other Operating Activity | 30,910 | 23,616 | 481 | -1,081 | -1,972 |
| Operating Cash Flow | $7,456 | $-3,235 | $3,339 | $6,508 | $3,194 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -1,500 | -810 | -5,737 | -499 | -263 |
| Purchase Sale Intangibles | -900 | N/A | N/A | N/A | N/A |
| Other Investing Activity | -900 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | $-2,400 | $-810 | $-5,737 | $-499 | $-263 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | N/A | 14,439 | N/A | 1,014 |
| Debt Repayment | -336 | 3,650 | -12,240 | N/A | -105 |
| Common Stock Issued | 19 | N/A | N/A | N/A | 42 |
| Other Financing Activity | -509 | -311 | -497 | -667 | -1,821 |
| Financing Cash Flow | $-826 | $3,339 | $1,702 | $-667 | $-870 |
| Beginning Cash Position | 7,539 | 8,245 | 8,940 | 3,598 | 1,537 |
| End Cash Position | 11,769 | 7,539 | 8,245 | 8,940 | 3,598 |
| Net Cash Flow | $4,230 | $-706 | $-696 | $5,343 | $2,061 |
| Free Cash Flow | |||||
| Operating Cash Flow | 7,456 | -3,235 | 3,339 | 6,508 | 3,194 |
| Capital Expenditure | -1,625 | -810 | -5,737 | -499 | -330 |
| Free Cash Flow | 5,831 | -4,045 | -2,398 | 6,010 | 2,864 |